Arcus Biosciences reported that casdatifan, its HIF-2α inhibitor, achieved progression-free survival beyond 12 months in late-line renal cell carcinoma patients. The data cover heavily pretreated individuals who progressed after two or more prior therapies, underscoring casdatifan’s potential in treatment-resistant kidney cancer.